Eli Lilly and Company (LLY)
Market Cap | 739.66B |
Revenue (ttm) | 34.12B |
Net Income (ttm) | 5.24B |
Shares Out | 950.77M |
EPS (ttm) | 5.80 |
PE Ratio | 134.13 |
Forward PE | 61.55 |
Dividend | $5.20 (0.67%) |
Ex-Dividend Date | Feb 14, 2024 |
Volume | 3,198,687 |
Open | 780.32 |
Previous Close | 778.18 |
Day's Range | 776.44 - 793.67 |
52-Week Range | 336.07 - 800.78 |
Beta | 0.34 |
Analysts | Strong Buy |
Price Target | 679.57 (-12.65%) |
Earnings Date | Apr 30, 2024 |
About LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the... [Read more]
Financial Performance
In 2023, LLY's revenue was $34.12 billion, an increase of 19.56% compared to the previous year's $28.54 billion. Earnings were $5.24 billion, a decrease of -16.08%.
Financial StatementsAnalyst Forecast
According to 23 analysts, the average rating for LLY stock is "Strong Buy." The 12-month stock price forecast is $679.57, which is a decrease of -12.65% from the latest price.
News
Three-Stock Lunch: Meta, Disney, and Eli Lilly
Eva Ados, ERShares chief investment strategist, joins 'Power Lunch' to discuss plays for three stocks, including Meta Platforms, Disney, and Eli Lilly.
Hennion & Walsh's Kevin Mahn on his top stock picks: CRWD, MSFT, LLY, RYTM
Kevin Mahn, Hennion & Walsh Asset Management president and CIO, joins 'Squawk Box' to discuss the latest market trends, why he believes AI isn't the only game in town for the markets, and more.
Here's Why Ozempic And Mounjaro Rivals Won't Topple Weight Loss Drugmakers Novo Nordisk And Eli Lilly Anytime Soon
The world is hooked on weight loss drugs and so is the pharmaceutical industry, but as Big Pharma's biggest players and upstart biotechs rush to join the booming market, experts tell Forbes the domina...
Here's how much people are willing to spend on weight loss drugs, according to a new survey
Some patients are willing to pay more for GLP-1 weight loss drugs like Wegovy than others — and it's strongly correlated to their annual income.
Medicare allows coverage of Wegovy for heart patients
Older adults may now get Medicare coverage for the popular obesity drug Wegovy, so long as they're using it to cut their risk of serious heart problems and not for weight loss alone, according to new ...
Eli Lilly and Novo can 'coexist for awhile' in the weight-loss drug space, says BMO's Evan Seigerman
Evan Seigerman, BMO Capital, joins 'Fast Money' to discuss BMO's inaugural GLP-1 conference.
A new study cites the health risks of intermittent fasting. Could it lift Ozempic sales?
A new medical study is raising concerns over whether intermittent fasting, a weight-loss method that's gained attention in recent years, could pose heart-health risks.
Should You Pick Eli Lilly Stock After A 4x Rise In Three Years?
Eli Lilly stock (NYSE: LLY) has seen phenomenal gains of 345% from levels of $170 in early January 2021 to around $755 now, vs. an increase of about 35% for the S&P 500 over this roughly three-year pe...
Lilly weight-loss drug Zepbound new US prescriptions surpass Wegovy for first time
Eli Lilly's powerful weight-loss drug Zepbound hit 77,590 new prescriptions in the U.S. for the week ending March 8, surpassing Novo Nordisk's rival obesity medicine Wegovy for the first time since it...
Call of the Day: Eli Lilly
JP Morgan is hiking Eli Lilly's price target to $850. The Investment Committee debate it.
Weight Loss Drugs Coming to Amazon
As more obesity treatments receive FDA approval, Eli Lilly is seeking new ways to get its weight loss products to the people. Get caught up on the latest news in under 60 seconds as Jenny Horne detail...
Lilly Picks Amazon Pharmacy to Dispense Diabetes and Obesity Meds
Drugmaker Eli Lilly has teamed with Amazon to deliver medications to patients' homes. The partnership, announced Wednesday (March 13), will see Amazon Pharmacy serve as a third-party dispensing partne...
Eli Lilly, Amazon Partner for Direct-to-Consumer Delivery of Zepbound, Other Drugs
Eli Lilly (LLY) and Amazon (AMZN) announced a partnership Wednesday that will allow Eli Lilly prescription drugs to be shipped through Amazon's online pharmacy, as Eli Lilly looks to expand its direct...
Eli Lilly strikes deal with Amazon Pharmacy for home delivery of Zepbound, other drugs
Eli Lilly & Co. has tapped Amazon.com Inc.'s Amazon Pharmacy to provide home delivery of certain Lilly medicines, including obesity drug Zepbound, the companies said Wednesday.
Amazon Will Now Deliver Eli Lilly Weight Loss Drug
The pharmaceutical giant has teamed up with Amazon Pharmacy to offer home delivery of certain medications through its drug-access platform.
Lilly partners with Amazon to deliver Zepbound and other drugs
Eli Lilly said on Wednesday it has brought on Amazon.com's pharmacy unit to deliver drug prescriptions sent to its direct-to-consumer service, LillyDirect.
Eli Lilly taps Amazon Pharmacy to help deliver weight loss drug Zepbound, other medicines to patients
Amazon Pharmacy second online pharmacy to partner with Eli Lilly's site, and could provide faster deliveries for certain patients.
Eli Lilly CEO on Fighting Obesity, Developing New Drugs
Eli Lilly chairman and CEO Dave Ricks says the company is working on expanding its medicine supply as the global obesity rate increases. Speaking with Bloomberg's Caroline Hyde at the Economic Club of...
Next thing: weight loss funds in the works
Next thing: weight loss funds in the works.
More than two-thirds of people with atopic dermatitis and skin of color experienced skin improvement in a first-of-its-kind lebrikizumab study
INDIANAPOLIS , March 10, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced results from a first-of-its-kind study of lebrikizumab specifically designed for people with skin of color and...
Eli Lilly's campaign seeks to resolve weight-loss drug misconceptions
Eli Lilly is launching a campaign aimed at informing consumers about the seriousness of diabetes as a disease and the appropriate use of its weight-loss-related drugs.
Eli Lilly's Alzheimer's Drug Release Delayed for FDA Investigation
Shares of Eli Lilly & Co. (LLY) were down more than 2% Friday after the pharmaceutical company announced that the Food and Drug Administration (FDA) wants more information about its experimental Alzhe...
Committee stocks on the move: Costco, Eli Lilly, Netflix, Google and Gold
The Investment Committee discuss stocks in their portfolio.